Susana Rodriguez

Susana Rodriguez

Auto-generated profile, based on publicly available information

Susana Rodriguez

Department of Physical Medicine and Rehabilitation (PMR), Neurorehabilitation Unit, Vall d'Hebron Hospital Universitari, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Neurophysiology
Verified
Journal Article
Open access
PDF file
BBBelén Rubio Ballester
Belén Rubio Ballester
MMMartina Maier
Martina Maier
ADArmin Duff
Armin Duff
MCMónica Cameirão
Mónica Cameirão
Sergi Bermúdez i BadiaSergi Bermúdez i Badia
Sergi Bermúdez i Badia
PVPaul F.M.J. Verschure
Paul F.M.J. Verschure
The impact of rehabilitation on post-stroke motor recovery and its dependency on the patient’s chronicity remain unclear. The field has widely accepted the notion of a proportional recovery rule with a “critical window for recovery” within the first 3–6 mo poststroke. This hypothesis justifies the general cessation of physical therapy at chronic stages. However, the limits of this critical window have, so far, been poorly defined. In this analysis, we address this question, and we further explore the temporal structure of motor recovery using individual patient data from a homogeneous sample of 219 individuals with mild to moderate upper-limb hemiparesis. We observed that improvement in body function and structure was possible even at late chronic stages. A bootstrapping analysis revealed a gradient of enhanced sensitivity to treatment that extended beyond 12 mo poststroke. Clinical guidelines for rehabilitation should be revised in the context of this temporal structure. NEW & NOTEWORTHY Previous studies in humans suggest that there is a 3- to 6-mo “critical window” of heightened neuroplasticity poststroke. We analyze the temporal structure of recovery in patients with hemiparesis and uncover a precise gradient of enhanced sensitivity to treatment that expands far beyond the limits of the so-called critical window. These findings highlight the need for providing therapy to patients at the chronic and late chronic stages.

7 August 2017 in JMIR Serious Games
Verified
Journal Article
Open access
BBBelén Rubio Ballester
Belén Rubio Ballester
JNJens Nirme
Jens Nirme
ICIrene Camacho
Irene Camacho
EDEsther Duarte
Esther Duarte
SRSusana Rodríguez
Susana Rodríguez
PVPaul F.M.J. Verschure
Paul F.M.J. Verschure
A multidisciplinary journal on gaming and gamification for health education/promotion, teaching and social change.

9 June 2015 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
BBBelén Rubio Ballester
Belén Rubio Ballester
JNJens Nirme
Jens Nirme
EDEsther Duarte
Esther Duarte
ACAmpar Cuxart
Ampar Cuxart
SRSusana Rodriguez
Susana Rodriguez
ADArmin Duff
Armin Duff
Stroke-induced impairments result from both primary and secondary causes, i.e. damage to the brain and the acquired non-use of the impaired limbs. Indeed, stroke patients often under-utilize their paretic limb despite sufficient residual motor function. We hypothesize that acquired non-use can be overcome by reinforcement-based training strategies. Hemiparetic stroke patients (n = 20, 11 males, 9 right-sided hemiparesis) were asked to reach targets appearing in either the real world or in a virtual environment. Sessions were divided into 3 phases: baseline, intervention and washout. During the intervention the movement of the virtual representation of the patients’ paretic limb was amplified towards the target. We found that the probability of using the paretic limb during washout was significantly higher in comparison to baseline. Patients showed generalization of these results by displaying a more substantial workspace in real world task. These gains correlated with changes in effector selection patterns. The amplification of the movement of the paretic limb in a virtual environment promotes the use of the paretic limb in stroke patients. Our findings indicate that reinforcement-based therapies may be an effective approach for counteracting learned non-use and may modulate motor performance in the real world.

29 June 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
MGMarina Gabriel-Salazar
Marina Gabriel-Salazar
AMAnna Morancho
Anna Morancho
SRSusana Rodriguez
Susana Rodriguez
XBXavi Buxó
Xavi Buxó
NGNicolás García-Rodríguez
Nicolás García-Rodríguez
ARAnna Rosell
Anna Rosell
Background: Rehabilitation therapy is the only available treatment for stroke survivors presenting neurological deficits; however, the underlying molecules and mechanisms associated with functional/motor improvement during rehabilitation are poorly understood. Objective: Our aim is to study the modulation of angiogenin and endothelial progenitor cells (EPCs) as repair-associated factors in a cohort of stroke patients and mouse models of rehabilitation after cerebral ischemia. Methods: The clinical study included 18 ischemic strokes admitted to an intensive rehabilitation therapy (IRT) unit, 18 non-ischemic controls and brain samples from three deceased patients. Angiogenin and EPCs were measured in blood obtained before and up to 6 months after IRT together with an extensive evaluation of the motor/functional status. In parallel, C57BL/6 mice underwent middle cerebral artery occlusion, and the pasta matrix reaching-task or treadmill exercises were used as rehabilitation models. Angiogenin RNA expression was measured after 2 or 12 days of treatment together with cell counts from EPCs cultures. Results: Brain angiogenin was identified in both human and mouse tissue, whereas serum levels increased after 1 month of IRT in association with motor/functional improvement. EPC populations were increased after stroke and remained elevated during follow-up after IRT. The mouse model of rehabilitation by the task-specific pasta matrix exercise increased the number of EPCs at 2 days and increased angiogenin expression after 12 days of rehabilitation. Conclusions: Angiogenin and EPCs are modulated by rehabilitation after cerebral ischemia, suggesting that both angiogenin and EPCs could serve as biomarkers of improvement during rehabilitation or future therapeutic targets.

1 November 2016 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
FMFeifei Ma
Feifei Ma
SRSusana Rodriguez
Susana Rodriguez
XBXavi Buxo
Xavi Buxo
AMAnna Morancho
Anna Morancho
IRIolanda Riba-Llena
Iolanda Riba-Llena
ARAnna Rosell
Anna Rosell

26 September 2019 in Planta Medica
Verified
Journal Article
Closed access
PDF file
Ramón CacabelosRamón Cacabelos
Ramón Cacabelos
ICIván Carrera
Iván Carrera
RARamón Alejo
Ramón Alejo
LFLucía Fernández-Novoa
Lucía Fernández-Novoa
PCPablo Cacabelos
Pablo Cacabelos
JCJUAN C CARRIL
JUAN C CARRIL
Atremorine is a novel bioproduct with neuroprotective effects on dopaminergic neurons and a natural L-DOPA donor in Parkinsonʼs disease (PD). In the present study, we show the effects of a single dose of Atremorine (5 g, p. o.) on plasma dopamine (DA) response and brain function in PD (n = 183) and the influence that pathogenic (LRRK2), metabolic (CYP2D5, CYP2C9, CYP2C19, CYP3A5, NAT2), transporter (ABCB1), pleiotropic (APOE), and detoxifying genes (CYP1B1, GSTT1, GSTP1, GSTM1, SOD2) involved in the pharmacogenetic network exerts on Atremorine-induced DA response. Over 90% of PD patients at diagnosis show plasma DA levels below 20 pg/mL. Atremorine induces DA synthesis causing a significant increase in plasma DA levels 1 h after administration in practically 100% of patients. Females tend to show lower basal DA levels than males and the response of DA to Atremorine is stronger in males than in females. Atremorine-induced DA response is pharmacogenotype-specific and lasts from 6 – 12 h depending upon the pharmacogenetic profile of each patient. Genetic variants in pathogenic genes, metabolic genes, and genes involved in the detoxification processes affect the response of DA to Atremorine in a genotype-specific manner. Atremorine or any of its bioactive components can cross the blood-brain barrier and improve brain function and motor function, as revealed by the reduction in slow wave activity in brain mapping and psychometric assessment, respectively. Atremorine is a selective neuroprotective agent for dopaminergic neurons with prophylactic and therapeutic potential in PD.